PortalPublikationenNeutrophil Gelatinase-Associated Lipocalin Measured on Clini...

Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis

Standard

Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis. / Albert, Christian; Zapf, Antonia; Haase, Michael; Röver, Christian; Pickering, John W; Albert, Annemarie; Bellomo, Rinaldo; Breidthardt, Tobias; Camou, Fabrice; Chen, Zhongquing; Chocron, Sidney; Cruz, Dinna; de Geus, Hilde R H; Devarajan, Prasad; Di Somma, Salvatore; Doi, Kent; Endre, Zoltan H; Garcia-Alvarez, Mercedes; Hjortrup, Peter B; Hur, Mina; Karaolanis, Georgios; Kavalci, Cemil; Kim, Hanah; Lentini, Paolo; Liebetrau, Christoph; Lipcsey, Miklós; Mårtensson, Johan; Müller, Christian; Nanas, Serafim; Nickolas, Thomas L; Pipili, Chrysoula; Ronco, Claudio; Rosa-Diez, Guillermo J; Ralib, Azrina; Soto, Karina; Braun-Dullaeus, Rüdiger C; Heinz, Judith; Haase-Fielitz, Anja.

in: AM J KIDNEY DIS, Jahrgang 76, Nr. 6, 12.2020, S. 826-841.e1.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Albert, C, Zapf, A, Haase, M, Röver, C, Pickering, JW, Albert, A, Bellomo, R, Breidthardt, T, Camou, F, Chen, Z, Chocron, S, Cruz, D, de Geus, HRH, Devarajan, P, Di Somma, S, Doi, K, Endre, ZH, Garcia-Alvarez, M, Hjortrup, PB, Hur, M, Karaolanis, G, Kavalci, C, Kim, H, Lentini, P, Liebetrau, C, Lipcsey, M, Mårtensson, J, Müller, C, Nanas, S, Nickolas, TL, Pipili, C, Ronco, C, Rosa-Diez, GJ, Ralib, A, Soto, K, Braun-Dullaeus, RC, Heinz, J & Haase-Fielitz, A 2020, 'Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis', AM J KIDNEY DIS, Jg. 76, Nr. 6, S. 826-841.e1. https://doi.org/10.1053/j.ajkd.2020.05.015

APA

Albert, C., Zapf, A., Haase, M., Röver, C., Pickering, J. W., Albert, A., Bellomo, R., Breidthardt, T., Camou, F., Chen, Z., Chocron, S., Cruz, D., de Geus, H. R. H., Devarajan, P., Di Somma, S., Doi, K., Endre, Z. H., Garcia-Alvarez, M., Hjortrup, P. B., ... Haase-Fielitz, A. (2020). Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis. AM J KIDNEY DIS, 76(6), 826-841.e1. https://doi.org/10.1053/j.ajkd.2020.05.015

Vancouver

Albert C, Zapf A, Haase M, Röver C, Pickering JW, Albert A et al. Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis. AM J KIDNEY DIS. 2020 Dez;76(6):826-841.e1. https://doi.org/10.1053/j.ajkd.2020.05.015

Bibtex

@article{e38e14f722624f5d9b2c92fba894214c,
title = "Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis",
abstract = "RATIONALE & OBJECTIVE: The usefulness of measures of neutrophil gelatinase-associated lipocalin (NGAL) in urine or plasma obtained on clinical laboratory platforms for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI-D) has not been fully evaluated. We sought to quantitatively summarize published data to evaluate the value of urinary and plasma NGAL for kidney risk prediction.STUDY DESIGN: Literature-based meta-analysis and individual-study-data meta-analysis of diagnostic studies following PRISMA-IPD guidelines.SETTING & STUDY POPULATIONS: Studies of adults investigating AKI, severe AKI, and AKI-D in the setting of cardiac surgery, intensive care, or emergency department care using either urinary or plasma NGAL measured on clinical laboratory platforms.SELECTION CRITERIA FOR STUDIES: PubMed, Web of Science, Cochrane Library, Scopus, and congress abstracts ever published through February 2020 reporting diagnostic test studies of NGAL measured on clinical laboratory platforms to predict AKI.DATA EXTRACTION: Individual-study-data meta-analysis was accomplished by giving authors data specifications tailored to their studies and requesting standardized patient-level data analysis.ANALYTICAL APPROACH: Individual-study-data meta-analysis used a bivariate time-to-event model for interval-censored data from which discriminative ability (AUC) was characterized. NGAL cutoff concentrations at 95% sensitivity, 95% specificity, and optimal sensitivity and specificity were also estimated. Models incorporated as confounders the clinical setting and use versus nonuse of urine output as a criterion for AKI. A literature-based meta-analysis was also performed for all published studies including those for which the authors were unable to provide individual-study data analyses.RESULTS: We included 52 observational studies involving 13,040 patients. We analyzed 30 data sets for the individual-study-data meta-analysis. For AKI, severe AKI, and AKI-D, numbers of events were 837, 304, and 103 for analyses of urinary NGAL, respectively; these values were 705, 271, and 178 for analyses of plasma NGAL. Discriminative performance was similar in both meta-analyses. Individual-study-data meta-analysis AUCs for urinary NGAL were 0.75 (95% CI, 0.73-0.76) and 0.80 (95% CI, 0.79-0.81) for severe AKI and AKI-D, respectively; for plasma NGAL, the corresponding AUCs were 0.80 (95% CI, 0.79-0.81) and 0.86 (95% CI, 0.84-0.86). Cutoff concentrations at 95% specificity for urinary NGAL were>580ng/mL with 27% sensitivity for severe AKI and>589ng/mL with 24% sensitivity for AKI-D. Corresponding cutoffs for plasma NGAL were>364ng/mL with 44% sensitivity and>546ng/mL with 26% sensitivity, respectively.LIMITATIONS: Practice variability in initiation of dialysis. Imperfect harmonization of data across studies.CONCLUSIONS: Urinary and plasma NGAL concentrations may identify patients at high risk for AKI in clinical research and practice. The cutoff concentrations reported in this study require prospective evaluation.",
author = "Christian Albert and Antonia Zapf and Michael Haase and Christian R{\"o}ver and Pickering, {John W} and Annemarie Albert and Rinaldo Bellomo and Tobias Breidthardt and Fabrice Camou and Zhongquing Chen and Sidney Chocron and Dinna Cruz and {de Geus}, {Hilde R H} and Prasad Devarajan and {Di Somma}, Salvatore and Kent Doi and Endre, {Zoltan H} and Mercedes Garcia-Alvarez and Hjortrup, {Peter B} and Mina Hur and Georgios Karaolanis and Cemil Kavalci and Hanah Kim and Paolo Lentini and Christoph Liebetrau and Mikl{\'o}s Lipcsey and Johan M{\aa}rtensson and Christian M{\"u}ller and Serafim Nanas and Nickolas, {Thomas L} and Chrysoula Pipili and Claudio Ronco and Rosa-Diez, {Guillermo J} and Azrina Ralib and Karina Soto and Braun-Dullaeus, {R{\"u}diger C} and Judith Heinz and Anja Haase-Fielitz",
note = "Copyright {\textcopyright} 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = dec,
doi = "10.1053/j.ajkd.2020.05.015",
language = "English",
volume = "76",
pages = "826--841.e1",
journal = "AM J KIDNEY DIS",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis

AU - Albert, Christian

AU - Zapf, Antonia

AU - Haase, Michael

AU - Röver, Christian

AU - Pickering, John W

AU - Albert, Annemarie

AU - Bellomo, Rinaldo

AU - Breidthardt, Tobias

AU - Camou, Fabrice

AU - Chen, Zhongquing

AU - Chocron, Sidney

AU - Cruz, Dinna

AU - de Geus, Hilde R H

AU - Devarajan, Prasad

AU - Di Somma, Salvatore

AU - Doi, Kent

AU - Endre, Zoltan H

AU - Garcia-Alvarez, Mercedes

AU - Hjortrup, Peter B

AU - Hur, Mina

AU - Karaolanis, Georgios

AU - Kavalci, Cemil

AU - Kim, Hanah

AU - Lentini, Paolo

AU - Liebetrau, Christoph

AU - Lipcsey, Miklós

AU - Mårtensson, Johan

AU - Müller, Christian

AU - Nanas, Serafim

AU - Nickolas, Thomas L

AU - Pipili, Chrysoula

AU - Ronco, Claudio

AU - Rosa-Diez, Guillermo J

AU - Ralib, Azrina

AU - Soto, Karina

AU - Braun-Dullaeus, Rüdiger C

AU - Heinz, Judith

AU - Haase-Fielitz, Anja

N1 - Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2020/12

Y1 - 2020/12

N2 - RATIONALE & OBJECTIVE: The usefulness of measures of neutrophil gelatinase-associated lipocalin (NGAL) in urine or plasma obtained on clinical laboratory platforms for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI-D) has not been fully evaluated. We sought to quantitatively summarize published data to evaluate the value of urinary and plasma NGAL for kidney risk prediction.STUDY DESIGN: Literature-based meta-analysis and individual-study-data meta-analysis of diagnostic studies following PRISMA-IPD guidelines.SETTING & STUDY POPULATIONS: Studies of adults investigating AKI, severe AKI, and AKI-D in the setting of cardiac surgery, intensive care, or emergency department care using either urinary or plasma NGAL measured on clinical laboratory platforms.SELECTION CRITERIA FOR STUDIES: PubMed, Web of Science, Cochrane Library, Scopus, and congress abstracts ever published through February 2020 reporting diagnostic test studies of NGAL measured on clinical laboratory platforms to predict AKI.DATA EXTRACTION: Individual-study-data meta-analysis was accomplished by giving authors data specifications tailored to their studies and requesting standardized patient-level data analysis.ANALYTICAL APPROACH: Individual-study-data meta-analysis used a bivariate time-to-event model for interval-censored data from which discriminative ability (AUC) was characterized. NGAL cutoff concentrations at 95% sensitivity, 95% specificity, and optimal sensitivity and specificity were also estimated. Models incorporated as confounders the clinical setting and use versus nonuse of urine output as a criterion for AKI. A literature-based meta-analysis was also performed for all published studies including those for which the authors were unable to provide individual-study data analyses.RESULTS: We included 52 observational studies involving 13,040 patients. We analyzed 30 data sets for the individual-study-data meta-analysis. For AKI, severe AKI, and AKI-D, numbers of events were 837, 304, and 103 for analyses of urinary NGAL, respectively; these values were 705, 271, and 178 for analyses of plasma NGAL. Discriminative performance was similar in both meta-analyses. Individual-study-data meta-analysis AUCs for urinary NGAL were 0.75 (95% CI, 0.73-0.76) and 0.80 (95% CI, 0.79-0.81) for severe AKI and AKI-D, respectively; for plasma NGAL, the corresponding AUCs were 0.80 (95% CI, 0.79-0.81) and 0.86 (95% CI, 0.84-0.86). Cutoff concentrations at 95% specificity for urinary NGAL were>580ng/mL with 27% sensitivity for severe AKI and>589ng/mL with 24% sensitivity for AKI-D. Corresponding cutoffs for plasma NGAL were>364ng/mL with 44% sensitivity and>546ng/mL with 26% sensitivity, respectively.LIMITATIONS: Practice variability in initiation of dialysis. Imperfect harmonization of data across studies.CONCLUSIONS: Urinary and plasma NGAL concentrations may identify patients at high risk for AKI in clinical research and practice. The cutoff concentrations reported in this study require prospective evaluation.

AB - RATIONALE & OBJECTIVE: The usefulness of measures of neutrophil gelatinase-associated lipocalin (NGAL) in urine or plasma obtained on clinical laboratory platforms for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI-D) has not been fully evaluated. We sought to quantitatively summarize published data to evaluate the value of urinary and plasma NGAL for kidney risk prediction.STUDY DESIGN: Literature-based meta-analysis and individual-study-data meta-analysis of diagnostic studies following PRISMA-IPD guidelines.SETTING & STUDY POPULATIONS: Studies of adults investigating AKI, severe AKI, and AKI-D in the setting of cardiac surgery, intensive care, or emergency department care using either urinary or plasma NGAL measured on clinical laboratory platforms.SELECTION CRITERIA FOR STUDIES: PubMed, Web of Science, Cochrane Library, Scopus, and congress abstracts ever published through February 2020 reporting diagnostic test studies of NGAL measured on clinical laboratory platforms to predict AKI.DATA EXTRACTION: Individual-study-data meta-analysis was accomplished by giving authors data specifications tailored to their studies and requesting standardized patient-level data analysis.ANALYTICAL APPROACH: Individual-study-data meta-analysis used a bivariate time-to-event model for interval-censored data from which discriminative ability (AUC) was characterized. NGAL cutoff concentrations at 95% sensitivity, 95% specificity, and optimal sensitivity and specificity were also estimated. Models incorporated as confounders the clinical setting and use versus nonuse of urine output as a criterion for AKI. A literature-based meta-analysis was also performed for all published studies including those for which the authors were unable to provide individual-study data analyses.RESULTS: We included 52 observational studies involving 13,040 patients. We analyzed 30 data sets for the individual-study-data meta-analysis. For AKI, severe AKI, and AKI-D, numbers of events were 837, 304, and 103 for analyses of urinary NGAL, respectively; these values were 705, 271, and 178 for analyses of plasma NGAL. Discriminative performance was similar in both meta-analyses. Individual-study-data meta-analysis AUCs for urinary NGAL were 0.75 (95% CI, 0.73-0.76) and 0.80 (95% CI, 0.79-0.81) for severe AKI and AKI-D, respectively; for plasma NGAL, the corresponding AUCs were 0.80 (95% CI, 0.79-0.81) and 0.86 (95% CI, 0.84-0.86). Cutoff concentrations at 95% specificity for urinary NGAL were>580ng/mL with 27% sensitivity for severe AKI and>589ng/mL with 24% sensitivity for AKI-D. Corresponding cutoffs for plasma NGAL were>364ng/mL with 44% sensitivity and>546ng/mL with 26% sensitivity, respectively.LIMITATIONS: Practice variability in initiation of dialysis. Imperfect harmonization of data across studies.CONCLUSIONS: Urinary and plasma NGAL concentrations may identify patients at high risk for AKI in clinical research and practice. The cutoff concentrations reported in this study require prospective evaluation.

U2 - 10.1053/j.ajkd.2020.05.015

DO - 10.1053/j.ajkd.2020.05.015

M3 - SCORING: Journal article

C2 - 32679151

VL - 76

SP - 826-841.e1

JO - AM J KIDNEY DIS

JF - AM J KIDNEY DIS

SN - 0272-6386

IS - 6

ER -